| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Platelet Aggregation Inhibitors | 23 | 2022 | 264 | 5.230 |
Why?
|
| Percutaneous Coronary Intervention | 17 | 2022 | 237 | 3.860 |
Why?
|
| Coronary Artery Disease | 20 | 2024 | 760 | 3.630 |
Why?
|
| American Heart Association | 26 | 2025 | 319 | 3.170 |
Why?
|
| Cardiology | 29 | 2021 | 501 | 3.120 |
Why?
|
| Practice Guidelines as Topic | 20 | 2020 | 1261 | 2.750 |
Why?
|
| Cardiovascular Diseases | 20 | 2025 | 1913 | 2.700 |
Why?
|
| Angioplasty, Balloon, Coronary | 18 | 2016 | 174 | 2.700 |
Why?
|
| Myocardial Infarction | 15 | 2020 | 1017 | 2.410 |
Why?
|
| Societies, Medical | 15 | 2019 | 687 | 1.980 |
Why?
|
| ST Elevation Myocardial Infarction | 7 | 2020 | 109 | 1.970 |
Why?
|
| Acute Coronary Syndrome | 11 | 2021 | 209 | 1.950 |
Why?
|
| Aspirin | 4 | 2021 | 224 | 1.600 |
Why?
|
| Myocardial Ischemia | 9 | 2022 | 340 | 1.600 |
Why?
|
| Advisory Committees | 10 | 2021 | 151 | 1.510 |
Why?
|
| Thrombosis | 6 | 2022 | 521 | 1.340 |
Why?
|
| Meditation | 2 | 2020 | 17 | 1.250 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 3 | 2021 | 46 | 1.140 |
Why?
|
| Research Report | 5 | 2021 | 75 | 1.120 |
Why?
|
| Pets | 2 | 2020 | 14 | 1.110 |
Why?
|
| United States | 45 | 2025 | 10822 | 1.060 |
Why?
|
| Cardiac Catheterization | 13 | 2022 | 633 | 1.000 |
Why?
|
| Humans | 110 | 2025 | 124502 | 0.870 |
Why?
|
| Pessimism | 1 | 2022 | 4 | 0.830 |
Why?
|
| Electrocardiography | 10 | 2020 | 970 | 0.810 |
Why?
|
| Fibrinolytic Agents | 8 | 2019 | 199 | 0.790 |
Why?
|
| Coronary Disease | 10 | 2020 | 655 | 0.790 |
Why?
|
| Mental Health | 2 | 2025 | 346 | 0.770 |
Why?
|
| Warfarin | 1 | 2022 | 118 | 0.750 |
Why?
|
| Stroke | 5 | 2022 | 976 | 0.740 |
Why?
|
| Erectile Dysfunction | 1 | 2024 | 180 | 0.730 |
Why?
|
| Angina, Unstable | 5 | 2014 | 52 | 0.730 |
Why?
|
| Mind-Body Therapies | 1 | 2021 | 11 | 0.730 |
Why?
|
| Sexual Behavior | 2 | 2014 | 247 | 0.720 |
Why?
|
| Stress, Psychological | 4 | 2022 | 557 | 0.710 |
Why?
|
| Yoga | 1 | 2020 | 12 | 0.680 |
Why?
|
| Cardiac Rehabilitation | 1 | 2020 | 24 | 0.670 |
Why?
|
| Ownership | 1 | 2020 | 31 | 0.670 |
Why?
|
| Disease Management | 4 | 2016 | 521 | 0.650 |
Why?
|
| Androgen Antagonists | 2 | 2010 | 118 | 0.640 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 122 | 0.620 |
Why?
|
| Heart Diseases | 2 | 2022 | 489 | 0.610 |
Why?
|
| Safety | 2 | 2008 | 218 | 0.550 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2017 | 101 | 0.550 |
Why?
|
| Enoxaparin | 6 | 2010 | 41 | 0.540 |
Why?
|
| Stents | 6 | 2017 | 884 | 0.540 |
Why?
|
| Secondary Prevention | 2 | 2017 | 216 | 0.540 |
Why?
|
| Coronary Artery Bypass | 6 | 2019 | 514 | 0.540 |
Why?
|
| Angina Pectoris | 4 | 2022 | 59 | 0.520 |
Why?
|
| Primary Prevention | 1 | 2017 | 167 | 0.520 |
Why?
|
| Hypertension | 3 | 2020 | 1288 | 0.510 |
Why?
|
| Risk Factors | 19 | 2024 | 10182 | 0.490 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 578 | 0.490 |
Why?
|
| Consensus | 5 | 2021 | 634 | 0.490 |
Why?
|
| Heparin, Low-Molecular-Weight | 3 | 2006 | 23 | 0.480 |
Why?
|
| Heart | 1 | 2019 | 723 | 0.470 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 859 | 0.460 |
Why?
|
| Anticoagulants | 7 | 2022 | 588 | 0.440 |
Why?
|
| Perioperative Care | 1 | 2016 | 196 | 0.440 |
Why?
|
| Evidence-Based Medicine | 6 | 2021 | 631 | 0.410 |
Why?
|
| Myocardial Revascularization | 3 | 2018 | 100 | 0.410 |
Why?
|
| Risk Assessment | 11 | 2022 | 3394 | 0.390 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 721 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2019 | 1106 | 0.380 |
Why?
|
| Microcirculation | 2 | 2022 | 93 | 0.360 |
Why?
|
| Prostatic Neoplasms | 2 | 2010 | 1532 | 0.360 |
Why?
|
| Professionalism | 2 | 2021 | 49 | 0.350 |
Why?
|
| Treatment Outcome | 19 | 2022 | 12322 | 0.330 |
Why?
|
| Guideline Adherence | 4 | 2020 | 380 | 0.320 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 187 | 0.310 |
Why?
|
| Clinical Competence | 5 | 2013 | 997 | 0.310 |
Why?
|
| Thrombolytic Therapy | 4 | 2020 | 204 | 0.310 |
Why?
|
| Brain | 1 | 2019 | 3003 | 0.290 |
Why?
|
| Coronary Angiography | 7 | 2020 | 427 | 0.280 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2021 | 440 | 0.280 |
Why?
|
| Heart Valve Diseases | 2 | 2021 | 169 | 0.280 |
Why?
|
| Cats | 2 | 2020 | 116 | 0.270 |
Why?
|
| Thoracic Surgery | 3 | 2014 | 158 | 0.270 |
Why?
|
| Prostheses and Implants | 1 | 2008 | 150 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2008 | 3576 | 0.260 |
Why?
|
| Ticlopidine | 2 | 2017 | 28 | 0.250 |
Why?
|
| Dogs | 2 | 2020 | 767 | 0.250 |
Why?
|
| Thrombectomy | 2 | 2016 | 103 | 0.240 |
Why?
|
| Maternal Health | 1 | 2025 | 19 | 0.240 |
Why?
|
| Quality Improvement | 3 | 2020 | 636 | 0.240 |
Why?
|
| Acute Disease | 7 | 2007 | 1108 | 0.230 |
Why?
|
| Perinatal Care | 1 | 2025 | 67 | 0.230 |
Why?
|
| Heart Valve Prosthesis | 4 | 2021 | 301 | 0.230 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 5 | 2006 | 61 | 0.220 |
Why?
|
| Endothelium, Vascular | 2 | 2017 | 518 | 0.220 |
Why?
|
| Drug Therapy, Combination | 4 | 2022 | 1158 | 0.220 |
Why?
|
| Intraoperative Care | 1 | 2003 | 104 | 0.210 |
Why?
|
| Male | 23 | 2024 | 61062 | 0.210 |
Why?
|
| Europe | 7 | 2019 | 352 | 0.210 |
Why?
|
| Employment | 2 | 2020 | 67 | 0.210 |
Why?
|
| No-Reflow Phenomenon | 2 | 2019 | 9 | 0.210 |
Why?
|
| Aortic Valve | 3 | 2015 | 442 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 491 | 0.200 |
Why?
|
| Vitamin K | 1 | 2022 | 36 | 0.200 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2012 | 26 | 0.200 |
Why?
|
| Folklore | 1 | 2022 | 1 | 0.200 |
Why?
|
| Educational Status | 2 | 2020 | 271 | 0.200 |
Why?
|
| Patient Care Team | 3 | 2013 | 547 | 0.200 |
Why?
|
| Heart-Assist Devices | 2 | 2008 | 1052 | 0.190 |
Why?
|
| Middle Aged | 17 | 2020 | 26526 | 0.190 |
Why?
|
| Benchmarking | 1 | 2022 | 134 | 0.190 |
Why?
|
| Coronary Circulation | 2 | 2019 | 211 | 0.180 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 644 | 0.180 |
Why?
|
| Certification | 2 | 2012 | 67 | 0.180 |
Why?
|
| Heart Valves | 1 | 2021 | 52 | 0.180 |
Why?
|
| Exercise | 2 | 2020 | 816 | 0.180 |
Why?
|
| Clinical Protocols | 2 | 2020 | 235 | 0.180 |
Why?
|
| Coronary Thrombosis | 1 | 2000 | 33 | 0.180 |
Why?
|
| Peptides | 2 | 2002 | 794 | 0.180 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 1662 | 0.180 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 9 | 0.180 |
Why?
|
| Inferior Wall Myocardial Infarction | 1 | 2020 | 8 | 0.180 |
Why?
|
| Aortic Valve Stenosis | 3 | 2013 | 337 | 0.170 |
Why?
|
| Time Factors | 5 | 2018 | 6285 | 0.170 |
Why?
|
| Heart Failure | 3 | 2022 | 2276 | 0.170 |
Why?
|
| Rural Health | 1 | 2020 | 48 | 0.170 |
Why?
|
| Marital Status | 1 | 2020 | 33 | 0.170 |
Why?
|
| Pregnancy Complications | 1 | 2025 | 507 | 0.170 |
Why?
|
| Tobacco Use | 1 | 2020 | 25 | 0.170 |
Why?
|
| Patient Selection | 3 | 2013 | 693 | 0.170 |
Why?
|
| Protective Factors | 1 | 2020 | 85 | 0.170 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 157 | 0.160 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2021 | 22 | 0.160 |
Why?
|
| Algorithms | 2 | 2016 | 1614 | 0.160 |
Why?
|
| Sex Distribution | 1 | 2020 | 300 | 0.160 |
Why?
|
| Age Distribution | 1 | 2020 | 414 | 0.160 |
Why?
|
| Hemoglobins | 1 | 2020 | 303 | 0.150 |
Why?
|
| Nutrition Surveys | 1 | 2020 | 291 | 0.150 |
Why?
|
| Hemodynamics | 3 | 2022 | 850 | 0.150 |
Why?
|
| Aged | 12 | 2020 | 19560 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1327 | 0.150 |
Why?
|
| Ethics, Medical | 1 | 2021 | 394 | 0.150 |
Why?
|
| Evidence-Based Practice | 2 | 2016 | 113 | 0.150 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 2127 | 0.150 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 359 | 0.150 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 375 | 0.150 |
Why?
|
| Vascular Diseases | 1 | 2019 | 166 | 0.150 |
Why?
|
| Leadership | 1 | 2020 | 228 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2005 | 368 | 0.150 |
Why?
|
| Heart Ventricles | 1 | 2022 | 769 | 0.140 |
Why?
|
| Education, Medical, Graduate | 2 | 2013 | 515 | 0.140 |
Why?
|
| Internet | 1 | 2020 | 383 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 351 | 0.140 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 606 | 0.140 |
Why?
|
| Atherectomy, Coronary | 1 | 1997 | 9 | 0.140 |
Why?
|
| Female | 20 | 2025 | 66333 | 0.140 |
Why?
|
| Triage | 1 | 2018 | 140 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2013 | 1490 | 0.140 |
Why?
|
| Freedom | 1 | 2017 | 18 | 0.140 |
Why?
|
| Ischemia | 1 | 2020 | 355 | 0.140 |
Why?
|
| Physicians | 2 | 2013 | 581 | 0.130 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 140 | 0.130 |
Why?
|
| Inpatients | 1 | 2020 | 499 | 0.130 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 560 | 0.130 |
Why?
|
| Heparin | 3 | 2003 | 228 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1419 | 0.130 |
Why?
|
| Drug-Eluting Stents | 1 | 2016 | 55 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 504 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2022 | 6084 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 436 | 0.130 |
Why?
|
| Surgeons | 1 | 2020 | 255 | 0.130 |
Why?
|
| Ascorbic Acid | 1 | 1996 | 78 | 0.130 |
Why?
|
| Smoking Cessation | 1 | 2017 | 197 | 0.130 |
Why?
|
| Pandemics | 2 | 2020 | 1105 | 0.130 |
Why?
|
| Blood Viscosity | 1 | 1995 | 13 | 0.120 |
Why?
|
| Diabetes Complications | 1 | 1997 | 198 | 0.120 |
Why?
|
| Biopsy | 3 | 2007 | 1239 | 0.120 |
Why?
|
| Coronary Vessels | 2 | 2016 | 538 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2017 | 186 | 0.120 |
Why?
|
| Clinical Trials as Topic | 4 | 2022 | 1090 | 0.120 |
Why?
|
| Status Asthmaticus | 1 | 1995 | 20 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 728 | 0.120 |
Why?
|
| Heart Function Tests | 1 | 2014 | 56 | 0.120 |
Why?
|
| Angina, Stable | 1 | 2014 | 4 | 0.120 |
Why?
|
| Endovascular Procedures | 2 | 2013 | 745 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2015 | 173 | 0.120 |
Why?
|
| Quality of Health Care | 2 | 2021 | 391 | 0.110 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2015 | 108 | 0.110 |
Why?
|
| World Health Organization | 1 | 2014 | 100 | 0.110 |
Why?
|
| Cause of Death | 2 | 2014 | 470 | 0.110 |
Why?
|
| Thiophenes | 1 | 2014 | 60 | 0.110 |
Why?
|
| Survival Rate | 2 | 2020 | 2028 | 0.110 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2014 | 28 | 0.110 |
Why?
|
| Hospitals, Veterans | 2 | 2013 | 359 | 0.110 |
Why?
|
| Adenosine | 1 | 2014 | 127 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 1995 | 153 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 2898 | 0.110 |
Why?
|
| Antioxidants | 1 | 1996 | 336 | 0.110 |
Why?
|
| Prevalence | 1 | 2020 | 2441 | 0.110 |
Why?
|
| Peripheral Arterial Disease | 1 | 2017 | 284 | 0.110 |
Why?
|
| Myocardial Reperfusion | 1 | 2013 | 72 | 0.100 |
Why?
|
| Equipment Design | 3 | 2008 | 598 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2014 | 90 | 0.100 |
Why?
|
| Exercise Test | 1 | 2014 | 250 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2020 | 849 | 0.100 |
Why?
|
| Piperazines | 1 | 2014 | 238 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 275 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2017 | 643 | 0.100 |
Why?
|
| Cross-Over Studies | 2 | 2012 | 312 | 0.100 |
Why?
|
| Myocardium | 2 | 2007 | 999 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2017 | 1330 | 0.100 |
Why?
|
| Smoking | 1 | 2017 | 1037 | 0.100 |
Why?
|
| Program Development | 1 | 2012 | 186 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2013 | 175 | 0.090 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2014 | 255 | 0.090 |
Why?
|
| Hospitalization | 2 | 2018 | 1776 | 0.090 |
Why?
|
| Point-of-Care Systems | 2 | 2003 | 172 | 0.090 |
Why?
|
| Adult | 7 | 2020 | 29407 | 0.090 |
Why?
|
| American Cancer Society | 1 | 2010 | 1 | 0.090 |
Why?
|
| Syndrome | 2 | 2003 | 1118 | 0.080 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2010 | 81 | 0.080 |
Why?
|
| Obesity | 2 | 2013 | 2266 | 0.080 |
Why?
|
| Animals | 4 | 2020 | 34157 | 0.080 |
Why?
|
| Morbidity | 1 | 2010 | 244 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2007 | 39 | 0.070 |
Why?
|
| Endocardium | 1 | 2007 | 49 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 5124 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 161 | 0.070 |
Why?
|
| Blood Coagulation Tests | 2 | 2004 | 60 | 0.070 |
Why?
|
| Electrodes, Implanted | 1 | 2008 | 168 | 0.070 |
Why?
|
| Betacoronavirus | 2 | 2020 | 287 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 236 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 267 | 0.070 |
Why?
|
| Myocarditis | 1 | 2007 | 131 | 0.070 |
Why?
|
| Young Adult | 1 | 2020 | 8976 | 0.060 |
Why?
|
| Pharmacists | 1 | 2006 | 84 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2007 | 225 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6487 | 0.060 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2005 | 14 | 0.060 |
Why?
|
| Cardiac Tamponade | 1 | 2005 | 37 | 0.060 |
Why?
|
| Pacemaker, Artificial | 1 | 2008 | 176 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 827 | 0.060 |
Why?
|
| Defibrillators, Implantable | 1 | 2008 | 192 | 0.060 |
Why?
|
| Pericardial Effusion | 1 | 2005 | 65 | 0.060 |
Why?
|
| Pyridines | 1 | 2006 | 228 | 0.060 |
Why?
|
| Pharmacokinetics | 1 | 2004 | 16 | 0.060 |
Why?
|
| Antithrombin III | 1 | 2004 | 25 | 0.060 |
Why?
|
| Hemorrhage | 2 | 2008 | 464 | 0.060 |
Why?
|
| Hematologic Agents | 1 | 2003 | 6 | 0.060 |
Why?
|
| Echocardiography | 3 | 2012 | 1055 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2003 | 32 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 486 | 0.050 |
Why?
|
| Coronary Stenosis | 1 | 2003 | 73 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2022 | 50 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2020 | 1025 | 0.050 |
Why?
|
| Kidney | 1 | 2009 | 1348 | 0.050 |
Why?
|
| Angiography | 2 | 2013 | 217 | 0.050 |
Why?
|
| Health Personnel | 1 | 2006 | 505 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 29 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2003 | 169 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2012 | 151 | 0.050 |
Why?
|
| Thrombin | 1 | 2001 | 59 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2007 | 862 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 138 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 1244 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2002 | 179 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 110 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2013 | 2089 | 0.040 |
Why?
|
| Social Isolation | 1 | 2020 | 42 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2000 | 213 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 54 | 0.040 |
Why?
|
| Contrast Media | 1 | 2003 | 471 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 224 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 549 | 0.040 |
Why?
|
| Registries | 1 | 2005 | 1419 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 678 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 299 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 443 | 0.040 |
Why?
|
| Education, Medical, Continuing | 2 | 2012 | 138 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 79 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 998 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 441 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 143 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 686 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 885 | 0.040 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2018 | 146 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 511 | 0.030 |
Why?
|
| Poverty | 1 | 2020 | 418 | 0.030 |
Why?
|
| Comorbidity | 2 | 2014 | 1527 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1276 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2013 | 4749 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 1997 | 204 | 0.030 |
Why?
|
| Classification | 1 | 2015 | 18 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 1600 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 430 | 0.030 |
Why?
|
| Prognosis | 2 | 2019 | 4572 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1807 | 0.030 |
Why?
|
| Vasodilation | 1 | 1996 | 190 | 0.030 |
Why?
|
| Societies, Nursing | 1 | 2014 | 3 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2003 | 810 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 439 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2810 | 0.030 |
Why?
|
| Incidence | 1 | 2001 | 3094 | 0.030 |
Why?
|
| Foundations | 1 | 2013 | 20 | 0.030 |
Why?
|
| Aortic Diseases | 1 | 2015 | 199 | 0.030 |
Why?
|
| Recurrence | 1 | 1997 | 1423 | 0.030 |
Why?
|
| Length of Stay | 2 | 2013 | 1309 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1997 | 1190 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 1996 | 445 | 0.030 |
Why?
|
| Patients | 1 | 2013 | 121 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2013 | 123 | 0.030 |
Why?
|
| Factor Xa Inhibitors | 2 | 2003 | 64 | 0.030 |
Why?
|
| Pregnancy | 1 | 2025 | 7170 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2013 | 200 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 218 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 750 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2010 | 125 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2020 | 16270 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 195 | 0.020 |
Why?
|
| Patient Safety | 1 | 2013 | 398 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2012 | 671 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2003 | 1630 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 275 | 0.020 |
Why?
|
| Public Policy | 1 | 2007 | 51 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 385 | 0.020 |
Why?
|
| Education, Nursing, Continuing | 1 | 2006 | 16 | 0.020 |
Why?
|
| International Cooperation | 1 | 2007 | 157 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2007 | 590 | 0.010 |
Why?
|
| Economics, Pharmaceutical | 1 | 2003 | 8 | 0.010 |
Why?
|
| Texas | 1 | 2012 | 3588 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2008 | 1178 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2005 | 477 | 0.010 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2003 | 14 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2008 | 1556 | 0.010 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2003 | 141 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2003 | 365 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1688 | 0.010 |
Why?
|
| Child | 1 | 2007 | 24436 | 0.000 |
Why?
|